Viatris Inc. 10-Q Summary: Q2 2026
Business Context and Reporting Period
This summary covers Viatris Inc.'s Form 10-Q for the quarterly period ended June 30, 2026. Viatris is a global healthcare company operating in four reportable segments: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company focuses on a diversified portfolio of generics, iconic brands, and innovative medicines.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) |
|---|---|---|
| Total Revenues | $3,756.8 million | $7,273.8 million |
| Net Sales | $3,745.9 million | $7,255.6 million |
| Gross Profit | $1,456.5 million (39% margin) | $2,613.7 million (36% margin) |
| Operating Earnings (Loss) | $6.3 million | $(73.4) million |
| Net Earnings (Loss) | $(118.8) million | $57.6 million |
| Diluted EPS | $(0.10) | $0.05 |
| Operating Cash Flow (YTD) | $770.1 million | |
| Cash and Equivalents (End of Period) | $886.5 million | |
| Total Debt (Current + Long-Term) | $13,351.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 5% year-over-year (YoY) in Q2 and 6% YoY for the six-month period. On a constant currency basis, net sales grew 4% in Q2 and 3% YTD, driven by new product launches (e.g., octreotide acetate) and strong performance in Greater China.
- Profitability Volatility: While Q2 2025 showed a net loss of $4.6 million, Q2 2026 resulted in a net loss of $118.8 million. However, the YTD 2026 net earnings of $57.6 million represent a significant improvement over the YTD 2025 net loss of $3,046.6 million, which was heavily impacted by a $2.94 billion goodwill impairment charge in Q1 2025.
- Expense Increases: SG&A expenses rose significantly in Q2 2026 ($1,134.5 million vs. $928.7 million in Q2 2025), primarily due to a $177.8 million charge related to the planned sale of Tyrvaya product rights. R&D expenses also increased to $248.3 million in Q2 2026, driven by development programs for selatogrel and cenerimod.
- Segment Performance: Greater China saw the strongest growth (21% increase in Q2 net sales), while JANZ and Emerging Markets experienced slight declines or flat performance on a constant currency basis.
Guidance, Outlook, and Risks
- Restructuring Program: The company is executing an Enterprise-Wide Strategic Review (EWSR) initiated in 2025, targeting a global workforce reduction of up to 10%. Total pre-tax charges are expected to range between $700 million and $850 million, with anticipated savings of $600 million to $700 million.
- Manufacturing Disruptions: A fire at the Nashik, India facility in February 2026 and ongoing FDA remediation at the Indore facility are impacting supply. Management anticipates a negative revenue impact of $100 million to $150 million in the second half of 2026 due to these disruptions.
- Divestitures: The company entered an agreement to sell Tyrvaya product rights for $30 million upfront plus potential milestones. A $177.8 million write-down was recorded in Q2 2026. Additionally, the sale of the Biocon Biologics equity stake was completed in July 2026.
- Litigation: Significant legal contingencies remain, including opioid-related settlements (accrued $281.3 million), drug pricing litigation, and intellectual property disputes. The company has accrued approximately $453 million for legal contingencies as of June 30, 2026.
- Capital Allocation: The company continues its share repurchase program (up to $2.0 billion authorized), repurchasing approximately $150 million in Q2 2026. A quarterly dividend of $0.12 per share was declared in August 2026.
Key Facts for Investor Verification
- Supply Chain Impact: Verify the extent of revenue loss in H2 2026 resulting from the Nashik fire and Indore FDA import alert.
- Restructuring Execution: Monitor the timing and magnitude of the remaining $600M-$750M in cash restructuring charges and the realization of projected savings.
- Legal Accruals: Review updates on opioid settlement payments and the outcome of the drug pricing bellwether trials scheduled for late 2026 and 2027.
- Debt Covenants: Confirm continued compliance with the 3.75:1.00 maximum leverage ratio covenant under the YEN Term Loan and Revolving Facility.
- Biocon Transaction: Assess the final financial impact of the Biocon Biologics divestiture, including the realized loss and the expiration of non-compete restrictions.